LncRNA HOXA11-AS Exerts Oncogenic Functions by Repressing p21 and miR-124 in Uveal Melanoma

Lü, Qianqian; Zhao, Na; Zha, Guiping; Wang, Huiyun; Tong, Qihu; Xin, Shuanghua

doi:10.1089/dna.2017.3808

Cited by 55 publications

(52 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous evidences have proved that lncRNA HOXA11‐AS expression was found to be overexpressed and played an oncogene in several tumours . Xu et al showed that HOXA11‐AS expression was up‐regulated in glioma cell lines and samples.…”

Section: Discussionmentioning

confidence: 99%

“…The underlying mechanism by how HOXA11‐AS involved in HCC tumorigenesis still remains to be researched. Growing studies indicated that lncRNAs acted crucial roles in several biological processes by playing as ceRNAs (competing endogenous RNAs) or molecular sponges to modulate‐specific miRNAs . Previous study showed that HOXA11‐AS functions as an oncogenic gene which enhanced glioma cell metastasis and growth by inhibiting miR‐214‐3p/EZH2 expression .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

LncRNA HOXA11‐AS promotes hepatocellular carcinoma progression by repressing miR‐214‐3p

Zhan

Xiao

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Accumulating studies supported that lncRNAs played important roles in tumorigenesis. LncRNA HOXA11‐AS was a novel lncRNA that has been proved to involved in several tumours. However, the role of HOXA11‐AS in the development of hepatocellular carcinoma (HCC) remains to be explained. In our study, we showed that HOXA11‐AS expression was up‐regulated in the HCC tissues, and the higher expression of HOXA11‐AS was associated with the advanced stage in the HCC samples. In addition, we indicated that the expression of HOXA11‐AS was up‐regulated in HCC cell lines (Hep3B, SMMC‐7721, MHCC97‐H and BEL‐7402) compared with normal liver cell lines (HL‐7702). Overexpression of HOXA11‐AS promoted HCC proliferation and invasion and induced the epithelial‐mesenchymal transition (EMT) and knockdown of HOXA11‐AS suppressed the HCC cell proliferation and invasion. However, we showed that miR‐214‐3p expression was down‐regulated in the HCC tissues and cell lines. Ectopic expression of miR‐214‐3p suppressed HCC cell proliferation and invasion. Furthermore, we indicated that overexpression of HOXA11‐AS decreased the miR‐214‐3p expression and the expression of miR‐214‐3p was negatively related with the HOXA11‐AS expression in HCC samples. Ectopic expression of HOXA11‐AS increased HCC proliferation and invasion and induced EMT through inhibiting miR‐214‐3p expression. These data suggested that HOXA11‐AS/miR‐214‐3p axis was responsible for development of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

LncRNA HOXA11‐AS promotes hepatocellular carcinoma progression by repressing miR‐214‐3p

Zhan

Xiao

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…HOXA11‐AS has been uncovered to be expressed at high levels in multiple human cancers, including hepatocellular carcinoma and uveal melanoma 18,19 . However, the expression status of HOXA11‐AS in PCa tissues and cells still needs detecting.…”

Section: Resultsmentioning

confidence: 99%

“…lncRNA PCA3 promotes PCa progression by targeting miR‐218‐5p/HMGB1 17 . lncRNA homeobox A11 antisense RNA (HOXA11‐AS) has been verified to elicit facilitating effect on the progression of many cancers 18,19 . However, the potential role of HOXA11‐AS in PCa remains to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

CTCF‐induced upregulation of HOXA11‐AS facilitates cell proliferation and migration by targeting miR‐518b/ACTN4 axis in prostate cancer

Xing

Liu

et al. 2020

The Prostate

View full text Add to dashboard Cite

Background Testified as crucial participators in different types of human malignancies, long noncoding RNAs (lncRNAs) have been revealed to exert a significant effect on the complicated courses of tumor progression. Although existing literatures have revealed the oncogenic role of lncRNA homeobox A11 antisense RNA (HOXA11‐AS) in multiple cancers, the underlying role of HOXA11‐AS in prostate cancer (PCa) and its potential molecular mechanism remains poorly understood. Aim To decipher the molecular performance of HOXA11‐AS in PCa. Methods The expression of HOXA11‐AS, miR‐518b and actinin alpha 4 (ACTN4) was detected by a real‐time quantitative polymerase chain reaction. Colony formation, EdU, flow cytometry, wound healing, and transwell assays were utilized to explore the biological role of HOXA11‐AS in PCa. The interaction between RNAs (CCCTC‐binding factor [CTCF], HOXA11‐AS, miR‐518b, and ACTN4) was tested via chromatin immunoprecipitation, luciferase reporter and RNA immunoprecipitation assays. Results HOXA11‐AS in PCa cells was expressed at high levels. Silenced HOXA11‐AS in PCa cells could lead to a significant elevation in the abilities of cell proliferation and migration whereas a remarkable declination in cell apoptosis capability. Subsequent molecular mechanism assays confirmed that HOXA11‐AS bound with miR‐518b and negatively regulates miR‐518b expression. Besides, HOXA11‐AS could regulate the expression of ACTN4 by sponging miR‐518b. Moreover, rescued‐function assays revealed that miR‐518b inhibition or ACTN4 upregulation reversed the repressive effect of HOXA11‐AS knockdown on PCa progression. Furthermore, CTCF was validated to activate HOXA11‐AS transcription in PCa cells. Conclusions CTCF‐induced upregulation of HOXA11‐AS facilitates PCa progression via miR‐518b/ACTN4 axis, providing a new target for PCa treatment.

show abstract

“…This malignancy can originate in the choroid (80%), ciliary body (12%) and iris (8%) [63]. Recent studies found that dysregulated lncRNAs were involved in the pathological development of UM, such as lncRNA-numb [64], PAUPAR [65], CANT1 [66], P2RX7-V3 [67], MALAT1 [68], RHPN1-AS1 [69], HOXA11-AS [70], PVT1 [71] and FTH1P3 [72]. Cheng et al found that the ectopic expression of hypermethylated in cancer 1 (HIC1) in UM could inhibit cell proliferation and invasion, and that this was down-regulated as a tumor suppressor in UM.…”

Section: Uveal Melanomamentioning

confidence: 99%

Long non‐coding RNAs in ocular diseases: new and potential therapeutic targets

et al. 2019

View full text Add to dashboard Cite

Long non‐coding RNAs (lncRNAs) are non‐protein coding transcripts containing more than 200 nucleotides. In the past, lncRNAs were considered as ‘transcript noise’ or ‘pseudogenes’ and were thus ignored. However, in recent years, lncRNAs have been proven to regulate gene expression at the epigenetic, transcriptional and translational level, and thereby influence cell proliferation, apoptosis, viability, immune response and oxidative stress. Furthermore, increasing evidence points to their involvement in different diseases, including cancer and heart diseases. Recently, lncRNAs were shown to be differentially expressed in ocular tissues and play a significant role in the pathogenesis of ophthalmological disorders such as glaucoma, corneal diseases, cataract, diabetic retinopathy, proliferative vitreoretinopathy and ocular tumors. In this review, we summarize the classification and mechanisms of known lncRNAs, while detailing their biological functions and roles in ocular diseases. Moreover, we provide a concise review of the clinical relevance of lncRNAs as novel, potential therapeutic targets in the treatment of eye diseases.

show abstract

LncRNA HOXA11-AS Exerts Oncogenic Functions by Repressing p21 and miR-124 in Uveal Melanoma

Cited by 55 publications

References 30 publications

LncRNA HOXA11‐AS promotes hepatocellular carcinoma progression by repressing miR‐214‐3p

LncRNA HOXA11‐AS promotes hepatocellular carcinoma progression by repressing miR‐214‐3p

CTCF‐induced upregulation of HOXA11‐AS facilitates cell proliferation and migration by targeting miR‐518b/ACTN4 axis in prostate cancer

Long non‐coding RNAs in ocular diseases: new and potential therapeutic targets

Contact Info

Product

Resources

About